Loading...
Market
How will Chimerix stock perform relative to biotech index post-FDA decision?
2
Resolution / Starting Odds
Outperforms biotech index • 25%
Performs in line with biotech index • 25%
Underperforms biotech index • 25%
No significant change • 25%
Stock market data and biotech index performance reports
Story
Chimerix Submits Dordaviprone NDA for Accelerated Approval to U.S. FDA for Recurrent H3 K27M-Mutant Diffuse Glioma, Secures $30 Million Funding
Dec 30, 2024, 12:02 PM
Chimerix, Inc. has submitted a New Drug Application (NDA) for accelerated approval of its drug, Dordaviprone, to the U.S. Food and Drug Administration (FDA). The application targets patients with recurrent H3 K27M-mutant diffuse glioma, a type of brain cancer. In addition, Chimerix has entered into a credit facility of up to $30 million with Silicon Valley Bank. This funding aims to provide access to additional capital during the upcoming investment cycle and to ensure the availability of Dordaviprone to as many patients as possible, should it receive approval.
View original story
Similar markets
No significant change • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease • 25%
Below $100 million • 25%
$100 million to $200 million • 25%
Above $300 million • 25%
$200 million to $300 million • 25%
Yes • 50%
No • 50%
Increase by less than 10% • 25%
Increase by 10% or more • 25%
Decrease by 10% or more • 25%
Decrease by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by over 10% • 25%
Increase by less than 10% • 25%
Increase by over 10% • 25%
Increase over 20% • 25%
Decrease • 25%
No change • 25%
Increase 0-20% • 25%
No • 50%
Yes • 50%
Fully utilized • 25%
Facility withdrawn • 25%
Not utilized • 25%
Partially utilized • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Decrease by 5-10% • 25%
Decrease by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by over 10% • 25%
Increase by over 10% • 25%
Decrease by 0-10% • 25%